Welcome to our dedicated page for Orthopedia SEC filings (Ticker: KIDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OrthoPediatrics Corp. filings document the regulatory record of a Nasdaq-listed medical device company focused on pediatric orthopedics. Its Form 8-K reports include quarterly and annual results, unaudited financial statements, revenue trends across Trauma and Deformity, Scoliosis, Sports Medicine/Other and OrthoPediatrics Specialty Bracing, as well as management guidance and investor presentation materials furnished under Regulation FD.
The company’s filings also cover governance and ownership matters through proxy statements, including board elections, executive compensation and equity awards. Material-event filings describe financing arrangements such as amendments to credit agreements and delayed draw term loan capacity, tying capital structure disclosures to the company’s operating and liquidity needs.
OrthoPediatrics Corp President and CEO David R. Bailey reported an open-market sale of 19,535 shares of common stock at $17.25 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations triggered when restricted stock vested, rather than as a discretionary portfolio move.
After this transaction, Bailey directly holds 298,020 shares of OrthoPediatrics common stock, which includes 187,891 shares of restricted stock awards. The sale represents only a portion of his overall equity position in the company.
OrthoPediatrics Corp President of Scoliosis Gregory A. Odle reported a stock compensation event combined with a tax-related share sale. He received a grant of 47,380 shares of common stock as a restricted stock award. The next day, 8,433 shares were sold specifically to satisfy tax withholding obligations upon vesting of restricted shares, according to the footnote. After these transactions, he directly holds 187,735 shares of common stock, which the disclosure states includes restricted stock awards totaling 121,054 shares.
OrthoPediatrics Corp General Counsel Daniel J. Gerritzen reported compensation-related stock activity. On March 15, he acquired 47,380 shares of common stock as a grant or award at $0.00 per share. On March 16, he sold 8,614 shares at $17.25 per share.
According to a footnote, the shares sold on March 16 were used to satisfy tax-withholding obligations tied to the vesting of restricted shares, rather than a discretionary sale. After these transactions, he directly holds 149,533 shares of common stock, which includes restricted stock awards totaling 121,054 shares.
OrthoPediatrics Corp. reports strong expansion as a pediatric-focused medical device and bracing company, targeting a global pediatric orthopedic market it estimates at $6.2 billion, including over $2.8 billion in the United States.
The company markets 87 surgical and specialized bracing systems across trauma and deformity, scoliosis and sports medicine, and has grown revenue from $10.2 million in 2011 to $236.3 million in the year ended December 31, 2025, a 25.2% compound annual growth rate. For 2025, trauma and deformity generated $166.3 million (70% of revenue), scoliosis $66.0 million (28%), and sports medicine/other $4.0 million (2%).
The report highlights an active acquisition program, including the 2024 purchase of Boston Brace International, Inc. and multiple O&P clinic roll-ups in the United States, Europe and Brazil, alongside new technology partnerships and an expanded credit and convertible note structure with Braidwell. As of December 31, 2025, OrthoPediatrics had consolidated total assets of $508.6 million, liabilities of $162.0 million, stockholders’ equity of $346.6 million, and 602 full-time equivalent employees.
OrthoPediatrics Corp. furnished an investor presentation outlining its 2025 performance and 2026 outlook. For 2025, revenue reached $236.3 million, up 15% from $204.7 million, with gross margin at 73%. The company still posted a net loss of $39.6 million, or $1.69 per diluted share, but delivered Adjusted EBITDA of $14.8 million and improved free cash flow to a $15 million outflow from $42 million the prior year.
The presentation highlights long-term double-digit revenue growth, a broad pediatric-focused product portfolio and contributions from acquisitions such as Boston Orthotics & Prosthetics. Management’s 2026 guidance targets revenue of $262.0 to $266.0 million, Adjusted EBITDA of about $25 million and breakeven free cash flow, emphasizing ongoing investment in new technologies and clinic expansion.